Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 8.6a

Immunosuppression Use for Induction, 1999 to 2008

Recipients with Kidney-Pancreas Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 941 915 891 905 871 881 903 924 862 836
With Immunosuppression Info 935 907 887 899 861 863 891 903 846 823
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 6.3% 3.0% 2.6% 2.8% 1.9% 2.5% 2.4% 0.7% 1.8% 1.5%
OKT3 15.5% 8.2% 3.6% 1.2% 0.3% 0.9% 0.4% 0.8% 1.2% 1.0%
Thymoglobulin 8.8% 22.9% 28.7% 39.2% 48.8% 44.3% 51.6% 61.5% 52.2% 59.8%
Zenapax 27.1% 21.8% 20.0% 16.4% 8.4% 5.0% 4.5% 5.1% 6.5% 6.1%
Simulect 17.1% 27.1% 31.1% 26.4% 16.0% 12.4% 8.2% 5.1% 5.7% 8.4%
Campath 0.0% 0.0% 0.0% 0.0% 7.8% 18.5% 14.8% 11.3% 13.1% 9.8%
No Induction Drugs Recorded 33.7% 26.8% 24.4% 23.5% 20.8% 21.2% 21.2% 18.1% 22.0% 16.6%


Source: OPTN/SRTR Data as of May 4, 2009.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.



PDF FormatRequires Adobe Acrobat Reader